IL-28 and IL-29: newcomers to the interferon family.

by: G Uzé, D Monneron

Biochimie, Vol. 89, No. 6-7. (l 2007), pp. 729-734.

View FullText article

DOI, Pubmed, Hubmed

Reviews [Write a review of this article]

There are no reviews of this article

Find related articles from these CiteULike users

bandrewfox

Find related articles with these CiteULike tags

il29, review

Abstract

IL-28 and IL-29 were recently described as members of a new cytokine family that shares with type I interferon (IFN) the same Jak/Stat signalling pathway driving expression of a common set of genes. Accordingly, they have been named IFN lambda. IFNs lambda exhibit several common features with type I IFNs: antiviral activity, antiproliferative activity and in vivo antitumour activity. Importantly, however, IFNs lambda bind to a distinct membrane receptor, composed of IFNLR1 and IL10R2. This specific receptor usage suggests that this cytokine family does not merely replicate the type I IFN system and justifies its designation as type III IFN by the nomenclature committee of the International Society of Interferon and Cytokine Research.

@article{citeulike:2821335, abstract = {IL-28 and IL-29 were recently described as members of a new cytokine family that shares with type I interferon (IFN) the same Jak/Stat signalling pathway driving expression of a common set of genes. Accordingly, they have been named IFN lambda. IFNs lambda exhibit several common features with type I IFNs: antiviral activity, antiproliferative activity and in vivo antitumour activity. Importantly, however, IFNs lambda bind to a distinct membrane receptor, composed of IFNLR1 and IL10R2. This specific receptor usage suggests that this cytokine family does not merely replicate the type I IFN system and justifies its designation as type III IFN by the nomenclature committee of the International Society of Interferon and Cytokine Research.}, address = {CNRS UMR 5124, University Montpellier II, Place Eug\`{e}ne Bataillon, 34095 Montpellier Cedex 5, France. uze@univ-montp2.fr}, author = {Uz\'{e}, G. and Monneron, D. }, citeulike-article-id = {2821335}, doi = {http://dx.doi.org/10.1016/j.biochi.2007.01.008}, issn = {0300-9084}, journal = {Biochimie}, keywords = {il29, review}, number = {6-7}, pages = {729--734}, posted-at = {2008-05-21 21:40:40}, priority = {2}, title = {IL-28 and IL-29: newcomers to the interferon family.}, url = {http://dx.doi.org/10.1016/j.biochi.2007.01.008}, volume = {89}, year = {2007} }

RIS record

TY - JOUR ID - citeulike:2821335 L3 - citeulike-article-id:2821335 TI - IL-28 and IL-29: newcomers to the interferon family. JF - Biochimie VL - 89 IS - 6-7 SP - 729 EP - 734 AD - CNRS UMR 5124, University Montpellier II, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France. uze@univ-montp2.fr SN - 0300-9084 N2 - IL-28 and IL-29 were recently described as members of a new cytokine family that shares with type I interferon (IFN) the same Jak/Stat signalling pathway driving expression of a common set of genes. Accordingly, they have been named IFN lambda. IFNs lambda exhibit several common features with type I IFNs: antiviral activity, antiproliferative activity and in vivo antitumour activity. Importantly, however, IFNs lambda bind to a distinct membrane receptor, composed of IFNLR1 and IL10R2. This specific receptor usage suggests that this cytokine family does not merely replicate the type I IFN system and justifies its designation as type III IFN by the nomenclature committee of the International Society of Interferon and Cytokine Research. KW - il29 KW - review AU - Uzé, G AU - Monneron, D PY - 2007///l UR - http://dx.doi.org/10.1016/j.biochi.2007.01.008 ER -

RIS BibTeX